Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

wesley_

01/10/19 11:49 AM

Post #3,167

Re: #3,166: @jfk - super buy if it gets hit by the

moving $6.50 name change: HROW

jfk

12/27/18 10:38 PM

Post #3,166

super buy if it gets hit by the overall market down at $4.10-$4.25. A $10 stock by 2020 at a minimum.

ireadthefins Free

12/11/18 8:39 AM

Post #3,165

IMMY - New Analyst Coverage with $10 target. Confident about operating cash flow, cancelled ATM with Cantor Fitz. Increased institutional interest. YoY revenue growth pretty impressive. Doing about ~$40MM/yr currently, with PPS at ~$5.50 market cap is ~$125MM. Compared to most of the other junk out there, this company is pretty undervalued right now, and growing rather quickly. Worth taking a look!

TrendTrade2016 PremiumMember

11/17/18 5:50 AM

Post #3,164

Re: #3,162: @TrendTrade2016 - IMMY the monster is mad and she is

IMMY i did sell...the PPS too ahead of the top bands!!

barknbud

11/16/18 11:06 AM

Post #3,163

Yeah---adding to more companies to the IPO/spinoff list is fuel for the fire---reminds me of Safeguard Scientific during the internet boom!

TrendTrade2016 PremiumMember

11/16/18 10:20 AM

Post #3,162

IMMY the monster is mad and she is running fast!!

TrendTrade2016 PremiumMember

11/16/18 10:07 AM

Post #3,161

Re: #3,160: @TrendTrade2016 - IMMY///find the good ones and hold!! With the

IMMY nice friday runner!!!

TrendTrade2016 PremiumMember

11/16/18 8:25 AM

Post #3,160

IMMY///find the good ones and hold!! With the big boards...patience is key!!!

Dennisb68

11/14/18 10:26 AM

Post #3,159

Up 17% today. Looking good here.

ireadthefins Free

11/08/18 7:13 AM

Post #3,158

Re: #3,157: @derkampfer - I believe in most simple terms it comes

Market capitalization = # common shares outstanding x price per share, and is the fair value “investors” deem the company to be worth. I don’t believe that by having a % ownership in another company, the market cap changes in relation to an IPO. Neither the # outstanding shares nor the PPS changes. (Well, technically the PPS changes if investor sentiment is positive or negative regarding ownership of IPO company.) My question is less about “market valuation” and more about actual reporting data (i.e. balance sheet, income statement, cash flow statement, and statement of changes in stockholder equity). In other words, how would the potential IPO of ETON affect IMMY’s reported financials, if at all?

derkampfer Free

11/07/18 11:59 PM

Post #3,157

Re: #3,156: @ireadthefins - Question:

I believe in most simple terms it comes down to market cap value. If company A with market cap value of $50M owns 30% of company B with market cap of $100M. Then add $30M in market cap to company A. So fair value of company A becomes more solidly valued at $80M at the time it (company B) goes public.

I’m sure I’m oversimplifying and some value of ETON is already baked into the IMMY stock price before its IPO but ...

IMMY value will directly relate to how ETON IPOs and its value after. At the moment I don’t believe we know the IPO stock price of ETON nor (more importantly) how it will perform in the open market.

ireadthefins Free

11/07/18 9:55 AM

Post #3,156

Question:

Admittedly, I have no experience or understanding of the effects of a company having a % owndership in another company that IPOs. How does the increase in cash and equity on the IPO company’s balance sheet affect the owner’s balance sheet and income statement (in accounting terms please)?

Thank you in advance.

Dennisb68

11/01/18 4:38 PM

Post #3,155

Another good day. I should have bought more.

derkampfer Free

10/29/18 9:16 AM

Post #3,154

Re: #3,153: @barknbud - MELT presentation:

Good find and thank you.

barknbud

10/29/18 8:01 AM

Post #3,153

MELT presentation:

http://secfilings.com/searchresultswide.aspx?link=2&filingid=13026047

Dennisb68

10/28/18 7:37 PM

Post #3,152

Bought in at 3.32 and so far been happy with the direction it's heading. Good luck to all.

barknbud

10/28/18 5:45 PM

Post #3,151

Re: #3,150: @ireadthefins - I must admit, I was excited listening to

Eton is pricing tomrw if all goes well. The underwriter leaves a lot to be desired but it sure beats no IPO.

Another item is the presentation of Melt in Chicago this weekend. Melt could be huge.

https://globenewswire.com/news-release/2018/10/16/1621771/0/en/ImprimisRx-to-feature-new-formulation-and-poster-presentation-on-MKO-Melt-at-the-upcoming-American-Academy-of-Ophthalmology-Meeting-in-Chicago.html

ireadthefins Free

10/27/18 3:45 PM

Post #3,150

Re: #3,149: @derkampfer - Key takeaways Q2 CC CEO Mark "it's an

I must admit, I was excited listening to the Q2 Earnings call, but at the same time the analyst in me reminded myself that it’s the CEO and CFO’s job to inspire and excite investors. It’s our job as investors to remain objective and stick to sound DD. That said, my current thoughts:

With regard to the short term stock price valuation of the company, we have to ask ourselves, what is the next catalyst that’s going to drive the price up or down? My guess would be Q3 Earnings in November. So what can we expect? My guess would be increased sales figures for the optics business, improving top line results. My second guess would be losses on the bottom line due to no gain from ‘deconsolidation’ as was the case in Q217 and Q218, which created short term positive EPS. I’m also interested in seeing how many new shares were sold.

I think longer term, the company is well positioned to grow. The next catalyst that may drive buying is the IPO. Does anyone know when this is expected to happen?

derkampfer Free

10/26/18 1:37 PM

Post #3,149

Re: #3,147: @ireadthefins - Technically, yes you are right the company did

Key takeaways Q2 CC CEO Mark "it's an exciting time""fantastic Q congratulations""turning the corner""move to $100M rev run rate""we are at 60% margins and grow to 70%""leading Opthomology co. in US""100% commission sales force (100 people) doubled"

They’re moving in the right direction. Add ETON and others and it all propels IMMYs bottom line.

Will be listening to Q3 CC closely.

TrendTrade2016 PremiumMember

10/26/18 5:46 AM

Post #3,148

Re: #3,145: @ireadthefins - IMMY What do you think is driving this

balance sheet is very good here...pretty low market cap!!

ireadthefins Free

10/26/18 1:11 AM

Post #3,147

Re: #3,146: @derkampfer - Not true. Company WAS PROFITABLE last Q. Don’t

Technically, yes you are right the company did report positive EPS (.11 diluted) in Q218. I was implying the company still isn't profitable from regular operations (sales revenue-cost to produce-cost to sell and maintain day to day operations), not including 'other income', which isn't recurring or part of normal business. Gains from the deconsolidation of the subsidiaries (Eton and, specifically Surface) recorded in other income are what boosted net income to positive in Q217 and Q218. A sustainable businesses strategy isn't to be an incubation machine for subsidiary spin-offs. In order to grow and become profitable, the company will have to increase sales and improve operating efficiency. I'm just wondering what the plan is to accomplish this?

derkampfer Free

10/26/18 12:36 AM

Post #3,146

Re: #3,145: @ireadthefins - IMMY What do you think is driving this

Not true. Company WAS PROFITABLE last Q. Don’t forget value of ETON is $20M+ add to market cap alone once IPO closes. Don’t forget value of Melt which had its own progress announcement this week. Margins are also expected to improve this quarter per CEO comments. Revenue growth y/oY was 85%.

Re-listen to last Q2 conference call. Tremendously good things happening in this small cap stock.

Stay tuned for more.

ireadthefins Free

10/25/18 11:52 PM

Post #3,145

Re: #3,144: @TrendTrade2016 - big board bio buy today....IMMY watch this bio

IMMY What do you think is driving this accumulation? At today's close, the market is now valuing the company at ~$90MM. Sales revenue has been ramping up at about 70% YOY as of 6/30/18, and the company will probably report annual sales revenue of ~$40MM. Still, not yet profitable as there are losses from operations in each quarter. Income from deconsolidation of subsidiaries is the only thing somewhat improving the bottom line. What is the company's strategy to become profitable?

TrendTrade2016 PremiumMember

10/25/18 4:09 PM

Post #3,144

big board bio buy today....IMMY watch this bio beast run!!!

barknbud

10/22/18 9:06 AM

Post #3,143

Record numbers and potentially IPOing three companies of which they will own a third.

Read up on Melt---potential game changer here---will be discussed this coming weekend at the Ophthalmology Conference in Chicago.

Dennisb68

10/17/18 3:46 PM

Post #3,142

Just came across this stock. Look's like it may have some possibilities.

Stratdan

04/11/18 7:12 AM

Post #3,141

BA! BOOM! BIATCH!!

Stratdan

03/18/18 7:37 AM

Post #3,140

Did You Not Hear Me? This Mother Come Monday Is Going to Blow The Fu*k Up!! Sorry Shorts.... HeHeHe,,

ClayTrader Free

01/30/18 5:19 PM

Post #3,139

* * $IMMY Video Chart 01-30-18 * *

Link to Video - click here to watch the technical chart video

Atlanta1

01/30/18 1:24 PM

Post #3,138

jumped in on the pullback to $1.94

fingers crossed

$IMMY

mkhazel

10/20/17 9:17 AM

Post #3,137

Apparently IMMY is owned by fitbit. Whoda thunk?

http://www.journalfinance.net/2017/10/oscillating-stock-imprimis-pharmaceuticals-inc-nasdaqimmy-fitbit-inc-nysefit-therapeuticsmd-inc-nasdaqtxmd/

ClayTrader Free

10/19/17 5:24 PM

Post #3,136

* * $IMMY Video Chart 10-19-17 * *

Link to Video - click here to watch the technical chart video

Hercules1

10/19/17 2:24 PM

Post #3,135

huge buying opportunity on this minor dip:

October 19, 2017
4:51 pm ET
*Imprimis CEO Mark Baum Tells Benzinga Co. Will Not Compound A Copy Of Restais As It Is Illegal, Will Use Patent-Pending Topical Cyclosporine Formulation To Compound Drug To The Individual Patient's Need From A Physician's Prescription
Benzinga

Hercules1

10/19/17 1:00 PM

Post #3,132

*Imprimis CEO Mark Baum Tells Benzinga Co. Will Not Compound A Copy Of Restais As It Is Illegal, Will Use Patent-Pending Topical Cyclosporine Formulation To Compound Drug To The Individual Patient's Need From A Physician's Prescription
Benzinga

Hercules1

10/19/17 12:43 PM

Post #3,131

Shares of Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) got a boost, shooting up 63 percent to $2.38 after the company announced Thursday the release of a 99-cent alternative to Allergan PLC (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease.

Hercules1

10/19/17 11:10 AM

Post #3,130

high for the day is $2.79.

it may hit $3 today.

Awl416

10/19/17 9:55 AM

Post #3,129

Out some 2.65 wow what a rush

Awl416

10/19/17 9:42 AM

Post #3,128

Thin to win wow

goingforittoday Free

06/24/17 2:47 PM

Post #3,127

wiltonio

03/29/17 6:15 AM

Post #3,126

Longboard Capital Advisors, LLC has filed a new 13G, reporting 6.58% ownership in $IMMY - https://fintel.io/so/us/immy

goingforittoday Free

02/28/17 10:32 AM

Post #3,125

Looks a lot like IMMY
True Nature Expands Board, Appoints Senior Pharma Executive http://finance.yahoo.com/news/true-nature-expands-board-appoints-140000192.html

EmptyBones PremiumMember

02/05/17 6:35 PM

Post #3,124

https://www.sec.gov/Archives/edgar/data/1360214/000149315217001109/xslF345X03/form4.xml

BrazenBull Free

04/05/16 1:21 AM

Post #3,123

Re: #3,122: @MasterBidder - Back in at 3.81

Any idea what these guys are doing now?

MasterBidder Free

02/12/16 1:36 PM

Post #3,122

Re: #3,121: @trickledownfacists - Sure did.

Back in at 3.81

trickledownfacists Free

12/17/15 5:36 PM

Post #3,121

Re: #3,120: @MasterBidder - That Martin clown that jacked price on the

Sure did.

MasterBidder Free

12/17/15 3:02 PM

Post #3,120

Re: #3,111: @trickledownfacists - Express Scripts Champions $1 per Pill Access to

That Martin clown that jacked price on the drug got arrested today and his company's stock halted

ronk

12/10/15 11:57 AM

Post #3,119

http://www.biopharmadive.com/news/senators-mull-speedier-generics-pathway-amid-outrage-over-turing-valeant-p/410548/

ronk

12/06/15 1:19 PM

Post #3,118

He just doesn't get it. Karma is gonna hurt someday.

“I probably would have raised prices higher, is probably what I should have done. I could have raised it higher and made more profits for our shareholders. Which is my primary duty.”

http://www.stardailystandard.com/business/martin-shkreli-i-ought-tove-raised-costs-greater/34838/

ronk

12/04/15 7:29 PM

Post #3,117

Re: #3,116: @Stock Guy777 - So Imprimis used to be transdel pharmaceuticals... Was this

Hey SG..

I guess the easiest way to answer that is referring to another post answering a concern about their split history:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118466368

In 2011 Transdel filed for a petition for reorganization under chapter 11 in Bankruptcy court. This timeline coincides with when Mark Baum was brought on as CEO; also 2011. Baum saw the company through the restructuring that year and they requested the court to dismiss the chapter 11 in November 2011. In Feb 2012, they changed their name to Imprimis.

I believe the company than seized the opportunity of compounding pharma on the passing of the Drug Quality and Security Act of 2013 which was put in place to employ strict guidance and oversight in the compounding pharmacy industry.

Not sure if you've read it but here's a link:

http://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/

Stock Guy777 Free

12/04/15 6:57 PM

Post #3,116

Re: #3,115: @ronk - SA article from yesterday:

So Imprimis used to be transdel pharmaceuticals...

Was this an OTC stock? Any information you know I would appreciate

https://www.lawinsider.com/contracts/4sDJVu6vj3XqN5DC7BZavb/transdel-pharmaceuticals/agreement/2015-02-02

Older

Imprimis Pharmaceuticals Inc (IMMY)

Followers	59	Posters	221
Posts (Today)	0	Posts (Total)	3167
Created	07/01/11	Type	Free
Moderators

Imprimis Pharmaceuticals, Inc.
NASDAQ: IMMY

Oct 22, 2015. Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from $13.50 per tablet to a reported $750.00 per tablet. The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children. According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.

Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as $99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient. For ordering information, please visit www.imprimiscares.com.

Mark L. Baum, CEO of Imprimis stated, "It is indisputable that generic drug prices have soared recently. While we have seen an increase in costs associated with regulatory compliance, recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population. While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider. This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable. In response to this recent case and others that we will soon identify, Imprimis is forming a new program called Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices."

Mr. Baum added, "Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs. Imprimis Cares and its team of compounding pharmacists will work with physicians and their patients to ensure they have affordable access to the medicines they need from the over 7,800 generic FDA-approved drugs. Imprimis Cares, available in all 50 states, will work with all third party insurers, pharmacy benefit managers and buying groups to offer its patient specific customizable compounded drug formulations at prices that ensure accessibility and that provide a reasonable profit for Imprimis. We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit."

Imprimis' finished compounded drug formulations do not have an FDA-approval label for recommended use. Imprimis compounded formulations are not FDA approved and may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Daraprim® is a registered trademark of Turing Pharmaceuticals LLC. Imprimis is not affiliated with Turing Pharmaceuticals LLC nor Daraprim®. Daraprim® is an FDA-approved drug. Please consult with your physician regarding which prescription options are most suitable for your specific needs.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.

http://www.imprimispharma.com/

Common stock outstanding after the offering 8,391,172

Cash and cash equivalents 18,059,285

MORE INFORMATION WILL BE ADDED TO THIS INTRO MESSAGE WHEN MADE AVAILABLE. THANKS FOR YOUR PATIENCE.

IMMY Latest News

No Recent News Available for this company!

More IMMY News

New Post

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Imprimis Pharmaceuticals Inc (IMMY)

IMMY Latest News